US › Healthcare

InMed Pharmaceuticals Inc (INM)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.32-0.75%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$2.06B

Revenue YoY

+115691.6%

Net profit

$-5.1M

EPS

$-1.43

Net margin

-0.2%

Key statistics

Market cap

$7.3M

Forward P/E

0.0

P/B

7.05

Book value

$0.20

EPS (TTM)

$-2.84

52-week high

$2.33

52-week low

$0.57

50-day MA

$1.39

200-day MA

$1.18

Beta

0.93

Analyst view

with an average price target of $20.00.

Shareholding

Insiders

0.06%

Institutions

53.30%

Largest institutional holders

Fund	Stake
ADAR1 Capital Management LLC	14.56%
Vivo Capital, LLC	14.53%
Squadron Capital Management LLC	5.92%
Ikarian Capital, LLC	4.46%
Ursa Fund Management, LLC	2.29%
Suvretta Capital Management, LLC	1.82%
BOOTHBAY FUND MANAGEMENT, LLC	1.35%
Sabby Management LLC	0.82%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InMed Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.